HOME › DRUGS › SELPERCATINIB
ACTIVE SUBSTANCE / INN

SELPERCATINIB

Brand name(s): RETEVMO, Retsevmo
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
NDA213246
Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms
ACTIVE SUBSTANCE
Selpercatinib
REGULATORS
FDA · EMA
SPONSORS / MAH
Eli Lilly Nederland B.V., ELI LILLY AND CO
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
RETEVMONDA213246ELI LILLY AND COPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
RetsevmoEli Lilly Nederland B.V.Authorised11/02/2021Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms

FULL INTELLIGENCE ON SELPERCATINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →